Effect of Chelation Therapy on Progressive Diabetic Nephropathy in Patients With Type 2 Diabetes and High-Normal Body Lead Burdens

Division of Clinical Toxicology, Department of Nephrology, Chang Gung Memorial Hospital, Lin-Kou Medical Center, Chang Gung University School of Medicine, Taipei, Taiwan, Republic of China.
American Journal of Kidney Diseases (Impact Factor: 5.76). 06/2012; 60(4):530-8. DOI: 10.1053/j.ajkd.2012.04.028
Source: PubMed

ABSTRACT A previous study in type 2 diabetic patients with high-normal body lead burdens showed that EDTA chelation therapy for 3 months slows progressive diabetic nephropathy during a 12-month follow-up. The effect of a longer course of therapy on kidney function decrease over a longer follow-up is not known.
A 12-month run-in phase, then a randomized single-blind study with a 27-month intervention.
University medical center; 50 patients (serum creatinine, 1.5-3.9 mg/dL) with high-normal body lead burden (≥80-<600 μg) were randomly assigned to the treatment and control groups.
The treatment group received weekly chelation therapy for 3 months to reduce their body lead burden to <60 μg and then as needed for 24 months to maintain this level. The control group received placebo for 3 months and then weekly for 5 weeks at 6-month intervals for 24 months.
The primary end point was change in estimated glomerular filtration rate (eGFR) over time. A secondary end point was a 2-fold increase in baseline serum creatinine level or the requirement for renal replacement therapy.
Body lead burdens were assessed by EDTA mobilization tests and eGFR was calculated using the equation for Chinese patients with type 2 diabetes.
Mean baseline eGFRs in the treatment and control groups were similar. After 3 months of chelation therapy, the change in eGFR in the treatment group (+1.0±4.8 mL/min/1.73 m(2)) differed significantly from that in the control group (-1.5±4.8 mL/min/1.73 m(2); P = 0.04). In the subsequent 24-month intervention, the yearly rate of decrease in eGFR (5.6±5.0 mL/min/1.73 m(2) per year) in the treatment group was slower than that (9.2±3.6 mL/min/1.73 m(2) per year; P = 0.04) in the control group. 17 (68%) control-group patients and 9 (36%) treatment-group patients achieved the secondary end point.
Small sample size, not double blind.
A 27-month course of EDTA chelation therapy retards the progression of diabetic nephropathy in type 2 diabetic patients with high-normal body lead burdens.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In the present review we provide an update of the appropriate use of chelating agents in the treatment of intoxications with compounds of mercury, lead and copper. The relatively new chelators meso-2,3-dimercaptosuccinic acid (DMSA) and 2,3-dimercapto-propanesulphonate (DMPS) can effectively mobilize deposits of mercury as well as of lead into the urine. These drugs can be administered orally and have relatively low toxicity compared to the classical antidote dimercaptopropanol (BAL). D-penicillamine has been widely used in copper overload, although 2,3-dimercaptosuccinic acid or tetrathiomolybdate may be more suitable alternatives today. In copper-toxicity, a free radical scavenger might be recommended as adjuvant to the chelator therapy.
    Journal of Trace Elements in Medicine and Biology 05/2014; DOI:10.1016/j.jtemb.2014.04.010 · 2.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Kidney disease disproportionately affects racial and ethnic minority populations, the poor, and the socially disadvantaged. The excess risk of kidney disease among minority and disadvantaged populations can only be partially explained by an excess of diabetes, hypertension, and poor access to preventive care. Disparities in the environmental exposure to nephrotoxicants have been documented in minority and disadvantaged populations and may explain some of the excess risk of kidney disease. High-level environmental and occupational exposure to lead, cadmium, and mercury are known to cause specific nephropathies. However, there is growing evidence that low-level exposures to heavy metals may contribute to the development of CKD and its progression. In this article, we summarize the excess risk of environmental exposures among minority and disadvantaged populations. We also review the epidemiologic and clinical data linking low-level environmental exposure to lead, cadmium, and mercury to CKD and its progression. Finally, we briefly describe Mesoamerican nephropathy, an epidemic of CKD affecting young men in Central America, which may have occupational and environmental exposures contributing to its development. Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
    Advances in Chronic Kidney Disease 01/2015; 22(1). DOI:10.1053/j.ackd.2014.09.003 · 1.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: S ince its earliest description in 1863 in France by Lancereaux, chronic lead nephropathy has been recognized in diverse settings, including episodic high exposure in the workplace and continuous low-level environmental exposure. 1 Later, clusters of chronic lead nephropathy cases between 1915 and 1935 were linked to childhood lead poisoning from ingestion of lead-based paint in Queensland, Australia, 2,3 and dur-ing the 1950s, to lead-contaminated moonshine whiskey in the southern United States. 1 Despite continued reports of chronic lead nephropathy from both occupational and nonoccupational settings, 1,4,5 the role of lead in kidney disease has been controver-sial and some authors have even questioned the very existence of chronic lead nephropathy. 6,7 Amidst this growing skepticism, this issue of AJKD presents a study by Chowdhury et al 8 reporting an increased risk of end-stage renal disease (ESRD) in individuals exposed to lead, mostly in the occupational setting. The authors analyzed blood lead values from 58,307 men in 11 states that participated in the Adult Blood Lead Surveillance (ABLES) program sponsored by the National Institute for Occupational Safety and Health. Compared to US general population (adjusted for age, race, sex and calendar), the analysis showed an increased standardized incidence ratio of ESRD at 5 years or later in individuals with at least one blood lead value above 51 mg/dL, with a median
    American Journal of Kidney Diseases 07/2014; 64(1):1-3. DOI:10.1053/j.ajkd.2014.04.004 · 5.76 Impact Factor